RxDoctor Payments Data

Sally McFarland, MD

Internal Medicine · Fairfax, VANPI 1033220454

Payments from drug & device makers

$7,567in general payments, 2019–2025

Across 398 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$713
  • Lilly USA, LLC$548
  • Boehringer Ingelheim$515
  • Pfizer$500
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$7,563100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,567 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$62,696
Medicare patients
115
Services billed
711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide111$199,676
JardianceEmpagliflozin69$89,684
MounjaroTirzepatide45$55,417
FarxigaDapagliflozin Propanediol28$38,481
EliquisApixaban22$17,161
SynthroidLevothyroxine Sodium101$10,668
UnithroidLevothyroxine Sodium28$1,979
Rosuvastatin Calcium139$1,964
Atorvastatin Calcium127$1,572
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide31$1,170
Olmesartan Medoxomil27$844
Bupropion XlBupropion Hcl16$833
Ezetimibe21$732
Metformin Hcl67$668
Gabapentin28$574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,204$199,676111 claims
Boehringer IngelheimJardiance$515$89,68469 claims
Lilly USA, LLCMounjaro$548$55,41745 claims
AstraZenecaFarxiga$713$38,48128 claims
PfizerEliquis$500$17,16122 claims
AbbVieSynthroid$1,173$10,668101 claims
Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium$339$2,42871 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →